We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


evocatal and EUCODIS Bioscience Enter Into Collaboration Agreement

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "evocatal and EUCODIS Bioscience Enter Into Collaboration Agreement"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Industrial biotech companies EUCODIS Bioscience and evocatal have announced the formation of an alliance to jointly market the companies’ industrial enzyme products, including alcohol dehydrogenases, lipases, and other enzymes.

The two companies will leverage their knowledge of customers’ needs in their respective markets as well as their complementary resources to provide existing and future customers with a broader choice of novel enzymes and related services.

Both parties have already started to align their marketing and sales activities, including their product catalogs, and are representing and marketing each partner’s products at industry trade fairs, beginning with CPhI 2010, Paris, and Biotechnica 2010, Hannover.

Financial terms of the agreement are not being disclosed.

“We are excited about the potential of our alliance with evocatal, who combine an impressive entrepreneurial spirit with a deep understanding of developing innovative enzymes for the fine chemicals industry”, said Thomas Fischer, CEO, EUCODIS Bioscience.

Dr. Thorsten Eggert, CEO of evocatal, agreed: “We also see Eucodis as a strong, technology-driven company with a solid portfolio of branded products. By forming this partnership we truly join our forces allowing the partners to significantly broaden their offerings to existing and to new customers”.

Dr. Michael Puls, CMO of evocatal, commented on the alliance: “We really team up in this process to significantly increase our customers’ benefit. Customers have now access to a larger enzyme portfolio through a single channel and also to a much broader service network.”

“We can thus provide more expertise in biocatalysis,” added Dr. Bhupinder Hundle, Senior VP Marketing and Sales, EUCODIS Bioscience. “This supports both of us in our continuous striving to provide the best possible service.”